Global Market: Spain
Spain, the 4th largest economy in the Eurozone, with a MedTech market concentrated heavily in Madrid and Catalonia, which together account for over 80% of medical equipment sales.
Population (24): 48 million GDP per Capital(24): $35,326
Life Expectancy(24): 84 yrs Currency: Euro (€, EUR)
MedTech Maturity level: Highly Mature
Population Dynamics: Aging (low birth rates & increased life expectancy)
Health System Structure
Governance model: Spain has a decentralized healthcare system that provides universal population coverage. With three sub-systems;
TheSistema Nacional de Salud(SNS), universal national health system that is financed through general taxation and provides coverage for all residents.
Mutual funds for specific groups, including MUFACE for civil servants, MUGEJU for the judiciary and ISFAS for the armed forces
The collaborating mutualities with Social Security, which cover work-related accidents and occupational diseases.
The Ministry of Health coordinates strategic planning and develops national regulations, each of the 17 the regions (autonomous communities) manage their own operational planning, purchasing and resource allocation.
Coverage model: Cost‑sharing is limited to a narrow set of services, and although households pay directly for care not covered by the SNS, out‑of‑pocket spending rarely results in catastrophic financial burden.
Medical device purchasing: Medical devices are acquired through public tenders, typically issued every two years and awarded for1–4‑year contract periods. Because each Autonomous Community manages its own budget and procurement processes, decision‑making criteria vary significantly across regions.
To to reduce cost, several regions operate regional purchasing agencies that negotiate contracts on behalf of all hospitals within the region. These agencies can standardize specifications, streamline procurement, and create more predictable purchasing cycles.
National centralized purchasing by tenders, where regions have the option to participate or not, is increasing. In some regions, authorities maintain a regional (sometimes referred to as a complementary or regional basket). These catalogues define, technical requirements, maximum allowable prices and approved vendors.
For inclusion in the national catalogue, new technology must undergo an evaluation of efficacy, cost and efficiency, effectiveness, safety, and therapeutic utility. In general devices must have a CE mark and demonstrate that they contribute meaningfully to prevention, diagnosis or treatment of diseases, extend life expectancy, autonomy or eliminate pain and suffering. They must also show improvement in safety, efficacy, effectiveness, efficiency or utility compared with existing alternatives.
Reimbursement Environment
Reimbursement mechanisms: Reimbursement environment is anchored in regional global budgets, with significant variation in how Autonomous Communities structure payments, manage device spending, and introduce innovation. While national policy defines the benefit basket, regions control the money, and this shapes how medical devices are actually funded and used.
Regions differ in how they structure payments with some regions using a mixed-payment model that combines global budgets and activity-related payments. A few regions, Catalonia, Andalucia, and Basque Country have piloted DRG-based payment systems, through these remain limited in scope and do not fully replace global budgeting.
Regions have the broad authority to limit the volume usage and set a ceiling price. Several regions (Andalucia, Castilla La Mancha, Castilla Leon, and Valencia) are developing list of approved therapies and products with defined maximum price.
The implications:
Products not included on these lists face significant barriers to hospital approval.
Even when clinically supported, off‑list technologies often require additional justification or administrative review.
Ceiling prices act as de facto reimbursement caps, shaping procurement behavior and vendor negotiations.
Hospital reimbursement operates under fixed annual budget, even when contracts reference activity levels.
This means:
Device reimbursement is effectively absorbed into the global budget, not paid separately.
Activity-based elements influence planning but do not materially change the financial ceiling
Hospitals must often seek additional innovation funding to adopt new or higher‑cost technologies, especially when they exceed standard price ceilings or require new workflows.
HTA maturity: Mature. Spain operates a coordinated national–regional HTA network (RedETS) led by the Ministry of Health and AETS‑ISCIII, with evaluations conducted by national and regional agencies.
Assessments apply cost‑effectiveness criteria, focus on appropriate use, and include post‑market follow‑up to improve quality and reduce clinical variability.
The system also collaborates to identify emerging and obsolete technologies, ensuring prioritization and alignment with evolving healthcare needs.
Pricing controls: Spain continues to rely on a mix of national and regional cost-containment measures. In the past decade, Spain has implemented temporary measures such as limits on “health tourism”, co-payments for non-urgent medical transport and creation of a state fund to finance cross-regional case.
Other systemic control levers that remain highly relevant include a national and regional budget reduction to reinforce the dominance of global budgets in hospitals, economies of scale through centralized purchasing, where national tenders and shared services providers reduce unit costs across multiple centers, and regional catalogues with maximum prices which define the ceiling price and significantly influence hospital-level adoption.
Coding environment: Diagnosis and intervention codes - ICD-10 MP for Diagnosis and ICD-10PSC for interventions
Key decision makers:
Ministry of Health Spain (MSND): Responsible for developing a national catalogue of services, laws and National quality plans or strategies. Medical device companies must be aligned with these measures in order to obtain funding.
Regional Health Authorities: Responsible for allocating the budget within regions, for regional strategies, for additional services for the region over the National Basket, for regional purchasing, positive list and regional tariffs; they participate in the Inter-territorial Council of the NHS, where they can make recommendations about Ministry of Health initiatives/strategies/Laws and can propose new National initiatives.
Hospital Managers: Responsible for allocating the budget within hospitals and responsible for final decision about tenders.
Hospital purchasers: Responsible for allocating hospital budget to specific therapies, participating in hospital tenders specification development.
Medical directors/ Head of Services: Responsible for specifying technical characteristics required for tenders, involved in decisions on therapy used and lobby for additional funding from the budget.
HTA bodies: Main responsibility is to conduct health technology assessment and make recommendations on adoption for the Ministry of health and regional health authorities and participate in development of clinical guidelines.
Value Drivers for Medical Technology
Clinical and Economic evidence expectations: Clinical and economic evidence is required at National level for technology evaluation, and economic data plays a critical role in value communication and supporting reimbursement and procurement discussions.
Innovation appetite: High, accelerating digital health ambitions, artificial intelligence and telehealth.
Local manufacturing incentives: The government has prioritized public investment in cutting-edge healthcare including research, innovation, precision medicine, digital transformation, and modernizing healthcare. Creating a supporting environment for MedTech development and adoption.
Digital readiness: The Spanish government adopted a Digital strategy in 2025 aiming to promote the digital transformation of the country through connectivity and incorporation of artificial intelligence.
Population & Demographic Baseline
Population size: 48 million
Age distribution(24): 21% aged 65+
Disease burden: 55% - 57.7% of the population with at least 1 chronic disease
Healthcare spending per capital(23): EUR 3,137
Healthcare workforce density(23):
Physicians per 1,000: 4.4
Nurses per 1,000: 5.9
Hospital beds per 1,000: 3.0
Economic Standing
Past
GDP growth patterns: Spain showed solid GDP growth of over 2% from 2016 - 2019 with a strong rebound post COVID-19 pandemic.
Healthcare spending as % of GDP: Spending has increased slightly from 9.3% in 2019 to 11.0% in 2020 and back to 10.8% in 2021.
Present
Current GDP and stability (24): Currently valued at 1.73 trillion USD, shows strong stability with projections indicating continued growth of roughly 2.1% - 2.3% in 2026.
Healthcare budget priorities: Spain’s current healthcare budget priorities center on reducing wait times, strengthen primary care, and accelerating digital transformation to improve access, efficiency, and system resilience.
MedTech market size in US millions: (Total Market size = (Total Local Production + Total Imports) - (Total Exports)
Total exports: 2,984
Total local production: 4,778
Total Imports: 6,317
Future
Demographic pressure scenarios: The Spanish population is ageing because of low birth rates and increases in life expectancy. The share of Spaniards aged 65 and over increased from 17% in 2000 to 20% in 2024, and is projected to rise further to 33% by 2050.
Expected Policy changes: Spain is expected to maintain cost-containment policies, while accelerating investment in three ares:
Replacing and upgrading of technical equipment and infrastructure to address aging capital stock.
A faster transition towards digitization and big-data capabilities to improve system efficiency and clinical decision-making
Expansion of public-private partnerships to support innovation, scale digital tools and modernize service delivery
Regional Opportunity & Risk Summary
Market attractiveness drivers
Population dynamics: An aging population and rising prevalence of chronic disease will continue to drive the demand for advanced medical technology across care settings.
Shift towards minimally invasive care: Lower treatment costs, shorter recovery times, and strong patient preference will sustain growing interest in minimally invasive technologies.
Expansion of digital and e-health solution: Demand for reputable e-health platforms, remote monitoring tools, and data driven clinical support systems in increasing as providers and patient seek more efficient, accessible models of care.
Key barriers to entry
Spain is a price sensitive market and foreign medical technology must conform to European Union and local standards.
Like other European Union markets, Spain continues to face strong cost-containment pressures that can limit procurement flexibility and slow growth. A compelling, evidence-driven value narrative is essential for medical technologies to secure adoption and overcome price-focused decision criteria.
Strategic entry recommendations
Establishing Local partnerships should be a core entry strategy for manufacturers seeking to expand into the broader EU market.
A well structured Market access strategy can strengthen negotiations, accelerate adoption and position the product competitively within the market. The strategy should combine the right entry points, have a compelling value narrative for your product, and a regional specific understand of procurement dynamics.
In conclusion, Spain is a compelling yet complex MedTech market: a universal, tax-funded health system with strong regional autonomy, accelerating digital ambitions, and a demographic profile that is aging faster than it’s economic growth. Success requires a clearly articulated value narrative and the ability to navigate regional specific procurement, budget constraints, and adoption pathways.
